Sono-Tek Corporation — Q3 FY2018 Form 10-Q
Reporting period: Quarter and nine months ended November 30, 2017. Sono-Tek develops, manufactures, sells, installs, and services ultrasonic spray-coating equipment, alongside rental real estate operations. Comparisons are with the corresponding 2016 periods unless noted.
Financial performance
| Metric | Three months | Nine months |
|---|---|---|
| Net sales | $2.982 million; +15% | $8.169 million; +14% |
| Gross profit / margin | $1.475 million / 49.5% (prior 47.7%) | $4.036 million / 49.4% (prior 46.0%) |
| Operating income (loss) | $198,370 (prior $54,206) | $316,641 (prior loss $175,737) |
| Net income | $194,442 (prior $62,342) | $264,956 (prior $28,460) |
| Basic and diluted EPS | $0.01 (prior $0.00) | $0.02 (prior $0.00) |
| Operating cash flow | Not separately presented | $1.405 million (prior $977,000) |
- Nine-month operating expenses rose $256,000 to $3.720 million, led by higher marketing and selling costs (+$211,000). R&D was roughly flat.
- Cash and cash equivalents were $1.699 million at November 30, while marketable securities were $4.447 million; together they totaled $6.146 million. Working capital was $6.483 million, and the current ratio was 3.88, down from 5.19 at February 28, 2017.
- Cash decreased $859,000 over the nine months to $1.699 million. Investing used $2.152 million, including $1.994 million for marketable securities and $158,000 for equipment. Operating cash flow included a $574,000 increase in customer deposits.
- Total debt was $1.065 million, down from $1.176 million at February 28; $154,475 was current. A $750,000 revolving credit line was undrawn. The term loan is secured by land and buildings, bears 4.15% interest, and is payable through January 2024.
- Total assets were $11.830 million and stockholders’ equity was $8.331 million. The real estate segment reported a nine-month net loss of $91,000, compared with a loss of $85,000.
Material changes and management commentary
- Ultrasonic spraying sales increased 15% in both the quarter and nine-month period. Management attributed growth primarily to stent-coating units, XYZ platforms, nozzles and ultrasonic generators, and ALIGN systems; declines in several other product lines partially offset gains.
- Spraying-segment gross margin improved to 49% for the nine months from 45%, and to 49% for the quarter from 47%. Management cited higher sales and fixed overhead costs remaining relatively constant as sales increased.
- Quarterly and annualized demand for certain systems can fluctuate. Management said product and market diversification reduces dependence on any one market, but does not eliminate demand variability.
- The prior-year nine-month period included $200,000 of life-insurance proceeds related to a former employee; other income consequently declined substantially year over year. Current-period other income included approximately $11,000 of realized investment gains and $6,000 of miscellaneous income.
Outlook, risks, and other matters
- The filing provides no quantified revenue or earnings guidance. Management describes new products, market expansion, and geographic reach as a foundation for future sales growth and improved profitability.
- Forward-looking risks identified include economic and business conditions, competition and technology changes, product development and market acceptance, financing adequacy, capacity additions, patent enforcement, and the ability to grow sales and sustain profitability.
- Management noted that actual results may differ from estimates and interim results are not necessarily indicative of full-year results. Stock-based compensation and income-tax accounting involve significant estimates.
- The company reported no legal proceedings, defaults on senior securities, or material changes in internal control over financial reporting; disclosure controls were assessed as effective. It reported no material foreign-currency exposure and considered interest-rate risk not material.
- The company adopted the deferred-tax balance-sheet classification standard retrospectively; it reclassified the February 2017 balance sheet without affecting earnings.
Important facts for investors to verify
- Whether the sales and margin improvement continues, particularly given quarter-to-quarter variability in key product lines.
- How much operating cash generation depends on customer deposits and whether inventory growth affects future cash conversion.
- The composition, valuation, and liquidity of the $4.447 million marketable-securities portfolio and the effects of investment-value changes.
- The economics and cash requirements of the real estate segment, which remained loss-making, and repayment terms for the secured term loan.
- Whether higher marketing and selling expenses produce sustained sales growth, and whether management provides later-period guidance.